Abstracts tagged "Disease Activity"

Abstract Number: 1983 • ACR Convergence 2020
Trajectories of Disease Activity in Patients with Newly Diagnosed Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Natalie Shiff¹, Peter Shrader², Colleen Correll³, Anne Dennos⁴, Thomas Phillips² and Timothy Beukelman⁵, ¹Florida, Gainesville, FL, ²Duke University, Durham, ³University of Minnesota, Minneapolis, MN, ⁴Duke University, Durham, NC, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To describe data-derived 2-year trajectories of disease activity in patients with recently diagnosed juvenile idiopathic arthritis (JIA) as measured by the clinical Juvenile Arthritis…
Abstract Number: 0166 • ACR Convergence 2020
Prevalence and Impact of Unacceptable Symptom State Among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation’s 2019 Annual Survey
Alexis Ogdie¹, George Gondo², Joseph Merola³, Stacie Bell⁴ and Alice Gottlieb⁵, ¹University of Pennsylvania, Philadelphia, PA, ²National Psoriasis Foundation, Portland, OR, ³Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ⁴National Psoriasis Foundation, Portland, ⁵Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Despite many efficacious therapies for PsA, many patients do not achieve remission. Ongoing disease activity leads to many downstream effects including diminished functional ability,…
Abstract Number: 0312 • ACR Convergence 2020
Dactylitis Is Associated with Greater Disease Severity, Ultrasound Synovitis, and Erosive Damage, in Very Early DMARD Naïve Psoriatic Arthritis
Sayam Dubash¹, Oras Alabas², Xabier Michelena², Gabriele De Marco³, Leticia Garcia-Montoya², Richard Wakefield², Ai Lyn Tan², Philip Helliwell⁴, Paul Emery⁵, Dennis McGonagle² and Helena Marzo-Ortega², ¹The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, England, United Kingdom, ²The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ³The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Treviglio, Italy, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: Dactylitis is a hallmark feature of Psoriatic arthritis (PsA), defined as a uniform swelling of a finger or toe (“sausage digit”). It is associated…
Abstract Number: 0573 • ACR Convergence 2020
Effects of Successive Switches of Two Different Biosimilars of Etanercept on Outcomes in Inflammatory Rheumatic Diseases in Daily Practice
Uta Kiltz¹, Styliani Tsiami², Xenofon Baraliakos¹ and Juergen Braun¹, ¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: A single switch from an originator to a biosimilar product has been shown to be safe and effective in the treatment of rheumatic musculoskeletal…
Abstract Number: 0827 • ACR Convergence 2020
Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis
Thomas Huizinga¹, Ernest Choy², Amy Praestgaard³, Hubert van Hoogstraten⁴, Patrick R LaFontaine³, Patricia Guyot⁵, Daniel Aletaha⁶, Ulf Müller-Ladner⁷, Yoshiya Tanaka⁸, Jeffrey R Curtis⁹ and Roy Fleischmann¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ³Sanofi, Cambridge, MA, ⁴Sanofi, Bridgewater, NJ, ⁵Sanofi, Chilly-Mazarin, France, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ⁷Department of Rheumatology and Clinical Immunology, Justus-Liebig University, Campus Kerckhoff, Bad Nauheim, Germany, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Sarilumab, an IL-6 receptor inhibitor, and upadacitinib, a Janus kinase (JAK) 1 inhibitor, are both approved for the treatment of patients with moderately to…
Abstract Number: 0940 • ACR Convergence 2020
In Patients with Inflammatory Arthritides Central Pain Sensitization Is Strictly Associated with Functional Disability
Giovanni Adami¹, Angelo Fassio¹, Elisabetta Gerratana², Alessandro Giollo¹, Camilla Benini¹, Luca Idolazzi¹, Elisabetta Vantaggiato¹, Davide Gatti¹ and Maurizio Rossini¹, ¹Rheumatology Unit, University of Verona, Verona, Italy, ²Rheumatology Unit, University of Messina, Messina, Italy
Background/Purpose: Long-term nociceptive pain, as in inflammatory arthritides, can cause Central Sensitization (CS) to pain. CS Inventory (CSI) is a validated screening instrument for clinicians to…
Abstract Number: 1228 • ACR Convergence 2020
Baricitinib 2-mg Provides Greater Improvements in Patient-Reported Outcomes Across All Disease Activity Levels Compared to Placebo: Post-hoc Analyses of RA-BEACON and RA-BUILD Trials
Clifton Bingham III¹, Bochao Jia², Jianmin Wu², Amanda Quebe², Carol Kannowski², Susan Otawa², Yun-Fei Chen², Kirstin Griffing², Dongyi He³ and Dalton Sholter⁴, ¹Johns Hopkins University, Baltimore, MD, ²Eli Lilly and Company, Indianapolis, IN, ³Shanghai Guanghua Hospital, Shanghai, Shanghai, China (People's Republic), ⁴University of Alberta, Edmonton, AB, Canada
Background/Purpose: Baricitinib (BARI) improved patient-reported outcomes (PROs) in patients with insufficient response or intolerance to ≥1 tumor necrosis factor inhibitors (TNFi) or other biological disease-modifying…
Abstract Number: 1357 • ACR Convergence 2020
Comparative Efficacy of Janus Kinase Inhibitors and TNF Inhibitors in Ankylosing Spondylitis: A Network Meta-Analysis
Adela Castro¹, Jesus Diaz², Guillermo Quiceno³ and John Cush⁴, ¹UT Southwestern, Dallas, TX, ²Universidad de los Andes, Dallas, TX, ³UT Southwestern Medical Center, Dallas, TX, ⁴University of Texas Southwestern Medical School, Dallas, TX
Background/Purpose: Active ankylosing spondylitis (AS) has been associated with poor quality of life and work disability in up to 50% of patients (1). There is…
Abstract Number: 1715 • ACR Convergence 2020
Longitudinal Patterns of Remission in Real-World Early Rheumatoid Arthritis Patients: Results from the Canadian Early Arthritis Cohort (CATCH)
Orit Schieir¹, Glen Hazlewood², Susan Bartlett³, Marie-France Valois³, Louis Bessette⁴, Gilles Boire⁵, Carol Hitchon⁶, Edward Keystone⁷, Janet Pope⁸, Carter Thorne⁹, Diane Tin⁹, Vivian Bykerk¹⁰ and Canadian Early Arthritis Cohort (CATCH) Investigators¹¹, ¹Canadian Early Arthritis Cohort Study, Montreal, Canada, ²University of Calgary, Calgary, AB, Canada, ³McGill University, Montreal, Canada, ⁴Laval University, Quebec, Canada, ⁵Universite de Sherbrooke, Sherbrooke, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷The Rebecca MacDonald Centre for Arthritis, Mt. Sinai Hospital, Toronto, Canada, ⁸Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Early diagnosis and rapid initiation of DMARDs following a treat-to-target approach have made remission a realizable goal for many persons living with RA. Despite…
Abstract Number: 1810 • ACR Convergence 2020
Complement Activation in Systemic Lupus Erythematosus Patients with Low Disease Activity Is Not Inhibited by Hydroxychloroquine
Anne Margrethe Troldborg¹, Annette Hansen², Kristian Stengaard-Pedersen² and Steffen Thiel², ¹Aarhus University Hospital, Arhus, Denmark, ²Aarhus University, Aarhus, Denmark
Background/Purpose: Mortality in patients with systemic lupus erythematosus (SLE) is significantly higher than in the general population. Treatment of SLE patients has improved, however, a…
Abstract Number: 1984 • ACR Convergence 2020
Causal Pathways to Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the ReACCh-Out Cohort
Kiem Oen¹, Jiahao Tian², Thomas Loughin², Roberta Berard³, Mercedes Chan⁴, Ciaran Duffy⁵, Brian Feldman⁶, Adam Huber⁷, Deborah Levy⁸, Dax G. Rumsey⁹, Natalie Shiff¹⁰, Shirley Tse¹¹, Lori Tucker⁴, Karen Watanabe-Duffy⁵ and Jaime Guzman¹², ¹University of Manitoba, Toronto, ON, Canada, ²Simon Fraser University, Burnaby, BC, Canada, ³London Health Sciences Centre, London, ON, Canada, ⁴BC Children's Hospital, Vancouver, BC, Canada, ⁵Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Florida, Gainesville, FL, ¹¹SickKids, Toronto, ON, Canada, ¹²University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: The relative roles of disease activity and disability as determinants of health-related quality of life (HRQoL) in children with JIA have been controversial; sometimes…
Abstract Number: 0169 • ACR Convergence 2020
Patient-Reported Outcomes Differentiate Between Remission and Low Disease Activity in Psoriatic Arthritis
Juliette Yedimenko¹, Jessica Walsh², Alexis Ogdie³, Yuxuan Jin¹, Soumya Reddy⁴, Jose Scher⁵ and M. Elaine Husni¹, ¹Cleveland Clinic, Cleveland, OH, ²University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ³Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴NYU School of Medicine, New York, NY, ⁵NYU School of Medicine, New York City
Background/Purpose: For psoriatic arthritis (PsA), several different composite instruments are available to define low disease activity (LDA) and remission (REM) targets for treatment. Patient-reported outcomes…
Abstract Number: 0313 • ACR Convergence 2020
Swollen Joints but Not Tender Joints Are Associated with Ultrasound Power Doppler Synovitis in Very Early DMARD Naive Psoriatic Arthritis
Sayam Dubash¹, Oras Alabas¹, Xabier Michelena¹, Leticia Garcia-Montoya¹, Gabriele De Marco², Mira Merashli³, Richard Wakefield¹, Philip Helliwell⁴, Ai Lyn Tan¹, Dennis McGonagle¹, Paul Emery⁵ and Helena Marzo-Ortega¹, ¹The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ²The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Treviglio, Italy, ³The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Beirut, Lebanon, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: Clinical tender and swollen joint counts are used for biologic drug eligibility and clinical trial inclusion criteria. Ultrasonography (US) adds to clinical examination as…
Abstract Number: 0616 • ACR Convergence 2020
Correlation Between Disease Activity and Perceived Economic Barriers to Care in a Population of African American Women with Systemic Lupus Erythematosus
Ashley White¹, Trevor Faith¹, Aissatou Ba¹, Viswanathan Ramakrishnan², Hetlena Johnson³, Jillian Rose⁴, Clara Dismuke-Greer⁵, Jim Oates⁶, Leonard Egede⁷ and Edith Williams¹, ¹Medical University of South Carolina, Charleston, SC, ²medical university of south carolina, south carolina, ³LupusCSC, Columbia, SC, ⁴Hospital for Special Surgery, New York, ⁵Palo Alto VA, Palo Alto, CA, ⁶Medical University of South Carolina, Charleston, SC, Charleston, SC, ⁷Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex, multifactorial disease with heterogeneous presentation. Disease activity – the number and severity of symptoms – can be…
Abstract Number: 0828 • ACR Convergence 2020
Clinical and Functional Response to Tofacitinib in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from a Phase 3b/4 Methotrexate Withdrawal Study
Stanley B Cohen¹, Yi-Hsing Chen², Naonobu Sugiyama³, Jose L Rivas⁴, Annette Diehl⁵, Tatjana Lukic⁶, Jerome Paulissen⁷, Haiyun Fan⁵, Tomohiro Hirose³ and Edward C Keystone⁸, ¹Metroplex Clinical Research Center, Dallas, TX, ²Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ³Pfizer Japan Inc, Tokyo, Japan, ⁴Pfizer SLU, Madrid, Spain, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Syneos Health, Morrisville, NC, ⁸Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: ORAL Shift (NCT02831855) was a 48-week Phase 3b/4 study, which demonstrated sustained efficacy/safety of tofacitinib modified release 11 mg once daily (QD) following MTX…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].